Reports Q1 revenue $218.8M, consensus $207.69M. Given the proposed acquisition of Shockwave Medical by Johnson & Johnson (JNJ), Shockwave Medical is withdrawing its FY24 guidance, previously issued on February 15. “The solid growth in the first quarter across geographies and products is a testament to the continued demand for our innovative solutions, driven by the unrelenting and extraordinary performance of our global Shockwave teams,” said Doug Godshall, CEO of Shockwave Medical. “Our team is looking forward to continuing our mission as part of Johnson & Johnson and to working together to bring our life-changing therapies to even more patients across the globe.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWAV:
- Shockwave Medical Reports First Quarter 2024 Financial Results
- SWAV Earnings this Week: How Will it Perform?
- Shockwave Medical Merges with Johnson & Johnson, Retains Key Leader
- ShockWave Medical data confirm consistent ‘real-world’ outcomes
- Shockwave Reducer Demonstrates Consistent, Positive Results in ‘Real-World’ Study